Patient Preferences Drive Treatment Options for Early HS

Treatment options for individuals with early-stage hidradenitis suppurativa (HS) vary depending on patient preference and how clinicians define “early” HS. This can be challenging because to date, no FDA-approved treatments exist for early-stage HS and only two biologics exist for moderate to severe disease. “For someone with occasional nodules and abscesses…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button